BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 31598757)

  • 21. Therapeutic Induction of Tertiary Lymphoid Structures in Cancer Through Stromal Remodeling.
    Johansson-Percival A; Ganss R
    Front Immunol; 2021; 12():674375. PubMed ID: 34122434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tertiary Lymphoid Structures in Colorectal Cancer Liver Metastases: Association With Immunological and Clinical Parameters and Chemotherapy Response.
    Ahmed A; Halama N
    Anticancer Res; 2020 Nov; 40(11):6367-6373. PubMed ID: 33109574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High endothelial venules proportion in tertiary lymphoid structure is a prognostic marker and correlated with anti-tumor immune microenvironment in colorectal cancer.
    Zhan Z; Shi-Jin L; Yi-Ran Z; Zhi-Long L; Xiao-Xu Z; Hui D; Pan YL; Pan JH
    Ann Med; 2023 Dec; 55(1):114-126. PubMed ID: 36503344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between Tertiary Lymphoid Structure and the Prognosis and Clinicopathologic Characteristics in Solid Tumors.
    Zhao Z; Ding H; Lin ZB; Qiu SH; Zhang YR; Guo YG; Chu XD; Sam LI; Pan JH; Pan YL
    Int J Med Sci; 2021; 18(11):2327-2338. PubMed ID: 33967609
    [No Abstract]   [Full Text] [Related]  

  • 25. Tertiary lymphoid structures are associated with higher tumor grade in primary operable breast cancer patients.
    Figenschau SL; Fismen S; Fenton KA; Fenton C; Mortensen ES
    BMC Cancer; 2015 Mar; 15():101. PubMed ID: 25884667
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The association of immune cell infiltration and prognostic value of tertiary lymphoid structures in gastric cancer.
    Yu JS; Huang WB; Zhang YH; Chen J; Li J; Fu HF; Wei ZW; He YL
    Neoplasma; 2022 Jul; 69(4):886-898. PubMed ID: 35603954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-infiltrating plasmacytoid dendritic cells are associated with survival in human colon cancer.
    Kießler M; Plesca I; Sommer U; Wehner R; Wilczkowski F; Müller L; Tunger A; Lai X; Rentsch A; Peuker K; Zeissig S; Seifert AM; Seifert L; Weitz J; Bachmann M; Bornhäuser M; Aust D; Baretton G; Schmitz M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33762320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting Tertiary Lymphoid Structures for Tumor Immunotherapy.
    Tang H; Qiu X; Timmerman C; Fu YX
    Methods Mol Biol; 2018; 1845():275-286. PubMed ID: 30141019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment.
    Chelvanambi M; Fecek RJ; Taylor JL; Storkus WJ
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33526609
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors.
    Zhang WH; Wang WQ; Han X; Gao HL; Xu SS; Li S; Li TJ; Xu HX; Li H; Ye LY; Lin X; Wu CT; Long J; Yu XJ; Liu L
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33055204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tertiary lymphoid structure score: a promising approach to refine the TNM staging in resected non-small cell lung cancer.
    Rakaee M; Kilvaer TK; Jamaly S; Berg T; Paulsen EE; Berglund M; Richardsen E; Andersen S; Al-Saad S; Poehl M; Pezzella F; Kwiatkowski DJ; Bremnes RM; Busund LR; Donnem T
    Br J Cancer; 2021 May; 124(10):1680-1689. PubMed ID: 33723388
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment
    Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity.
    Engelhard VH; Rodriguez AB; Mauldin IS; Woods AN; Peske JD; Slingluff CL
    J Immunol; 2018 Jan; 200(2):432-442. PubMed ID: 29311385
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of Tools for the Selective Visualization and Quantification of TLS-Immune Cells on Tissue Sections.
    Klein C; Devi-Marulkar P; Dieu-Nosjean MC; Germain C
    Methods Mol Biol; 2018; 1845():47-69. PubMed ID: 30141007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tertiary lymphoid structures in breast ductal carcinoma in situ correlate with adverse pathological parameters.
    Zeng L; Koh VCY; Chen XY; Tan PH
    Histopathology; 2023 Apr; 82(5):779-788. PubMed ID: 36635954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
    Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
    Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterogeneity in tertiary lymphoid structure B-cells correlates with patient survival in metastatic melanoma.
    Lynch KT; Young SJ; Meneveau MO; Wages NA; Engelhard VH; Slingluff CL; Mauldin IS
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical relevance of tertiary lymphoid structures in esophageal squamous cell carcinoma.
    Deguchi S; Tanaka H; Suzuki S; Natsuki S; Mori T; Miki Y; Yoshii M; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
    BMC Cancer; 2022 Jun; 22(1):699. PubMed ID: 35751038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas.
    Edmonds NL; Gradecki SE; Katyal P; Lynch KT; Stowman AM; Gru AA; Engelhard VH; Slingluff CL; Mauldin IS
    Oncoimmunology; 2023; 12(1):2164476. PubMed ID: 36632563
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrative analysis of tertiary lymphoid structures and immune microenvironment in patients with esophageal carcinoma.
    Yao Y; Xuan H; Wang J; Gong L; Gao W
    Tumori; 2023 Oct; 109(5):466-480. PubMed ID: 37249074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.